Weed Inc. Is Overvalued And Lost 666% More In The Nine Months Ended September 2018

About: WEED, Inc. (BUDZ), Includes: ACB, CGC, CNAB, CRON, MRRCF, TLRY
by: Bilbao Asset Management
This article is exclusive for subscribers.
Bilbao Asset Management
Long/short equity, value, special situations, growth at reasonable price

Arizona-based Weed Inc. focuses on the development of cannabis-based compounds for the treatment of human diseases.

For the nine months ended September 30, 2018, the company’s net loss was equal to -$22.15 million, 666% more than that in the nine months ended September 30, 2017.

The amount of total assets is increasing because of new acquisitions of properties, not as a result of R&D activities.

The total enterprise value equals $176 million. It seems too much. As of today, the company does not report revenues, reports total assets of $3.16 million, and no patents.

Like it happens many times on the OTC Markets, BUDZ’s float is very low, which could be perceived as very risky. Investors should be expecting massive amount of share price volatility.

Weed, Inc. (OTCPK:BUDZ) is building its facilities in Colorado and counts with experts in bio-molecular testing. With this in mind, the company seems well prepared to capitalize on the growing cannabis industry. Having